$FENC

FENNEC PHARMACEUTICALS INC. (FENC) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001211583 0001211583 2026-06-10 2026-06-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor

Raykov Rosty sold 9,747 shares of FENNEC PHARMACEUTICALS INC. (FENC) at $9.62 on 2026-06-01 under a Rule 10b5-1 trading plan.

Fennec Pharmaceuticals announced that four scientific abstracts regarding its PEDMARK sodium thiosulfate injection have been accepted for presentation at the ASCO26 scientific program. These abstracts will focus on clinical research, patient outcomes, and ototoxicity related to chemotherapy-induced hearing loss. This selection by the American Society of Clinical Oncology highlights Fennec’s ongoing contributions to the medical community, building on its recent fiscal year 2025 earnings release and calls for greater collaboration in global health.

B.Riley has initiated coverage on Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy rating and a $16 price target, citing significant undervaluation of its PEDMARK commercial potential. The firm highlights PEDMARK as the only FDA-approved therapy for cisplatin-induced hearing loss risk, with no approved competitors. Recent positive developments include record sales, an operating cash flow-positive quarter, and the company's full repayment of outstanding debt.

Southpoint Capital Advisors LP sold 1,000,000 shares of Adherex Technologies (NASDAQ:FENC) on December 24th at $7.50 per share, totaling $7.5 million and reducing its stake by 26.7%. This sale is part of an ongoing trend of disposals by Southpoint, indicating sustained insider selling pressure. Following the news, FENC shares traded down by 4.9% to $7.69 on higher-than-average volume, as analysts maintain a "Hold" consensus rating with a target price of $13.33.

Southpoint Capital Advisors LP has reduced its stake in Fennec Pharmaceuticals Inc. (TSE:FRX), selling 1 million common shares at USD$7.50 each. Following this transaction, Southpoint now holds approximately 2.7 million common shares, representing about 8% of Fennec's fully diluted share base, and indicated that its holdings might change further. While Fennec shows strong revenue growth, profitability issues and a weak balance sheet remain concerns, according to TipRanks' AI Analyst, Spark.

RESEARCH TRIANGLE PARK, N.C., Nov. 26, 2025 ( GLOBE NEWSWIRE ) -- Fennec Pharmaceuticals Inc. ( NASDAQ: FENC. TSX: FRX ) , a commercial stage specialty pharmaceutical company, today announced that the Company will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare ...

RESEARCH TRIANGLE PARK, N.C., Nov. 17, 2025 ( GLOBE NEWSWIRE ) -- Fennec Pharmaceuticals Inc. ( NASDAQ:FENC ) ( TSX:FRX ) ( "Fennec" or the "Company" ) , a specialty pharmaceutical company, today announced the closing of its underwritten registered public offering of 5,366,667 common shares ( ...

RESEARCH TRIANGLE PARK, N.C., Nov. 17, 2025 ( GLOBE NEWSWIRE ) -- Fennec Pharmaceuticals Inc. ( NASDAQ:FENC ) ( TSX:FRX ) ( "Fennec" or the "Company" ) , a specialty pharmaceutical company, today announced the closing of its underwritten registered public offering of 5,366,667 common shares ( ...

RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2025 ( GLOBE NEWSWIRE ) -- Fennec Pharmaceuticals Inc. ( NASDAQ:FENC ) ( TSX:FRX ) ( "Fennec" or the "Company" ) , a specialty pharmaceutical company, today announced that it intends to engage in a non-brokered offering of its common shares in Canada, at a ...